ArticleGenome medicine2026
Migration and tuberculosis transmission in Hamburg, Germany: insights from 25 years of molecular epidemiology.
Article in Genome medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTuberculosis (TB) epidemiology in low-incidence settings is increasingly influenced by the importation of Mycobacterium tuberculosis complex (Mtbc) strains from high-incidence regions. Globally, more virulent "generalist" lineages such as Lineage 2 (L2) and Lineage 4 (L4) contrast with geographically restricted "specialist" lineages (L1, L3, L5-L9), reflecting differences in transmissibility and adaptation. The introduction of strains of diverse lineages can alter local transmission dynamics and drug susceptibility patterns, underscoring the need for high-resolution genomic surveillance.
methodsWe performed whole genome sequencing (WGS) on 3,131 Mtbc strains collected from patients with TB in Hamburg, Germany, over 25 years (1997-2021). We analysed population structure and transmission dynamics in relation to patients' self-reported geographical origins.
resultsStrains from major Mtbc lineages L1-L6 and M. bovis were detected, with L4 strains being most prevalent (74.6%, n = 2,337). Lineage distribution shifted over time: L4 strains decreased from 83.5% in the first five years to 63.0% in the last five years, while L3 strains increased from 4.8% to 18.1%. These changes correlated with an increasing number of foreign-born patients rather than enhanced transmission of strains of specific lineages. L4 strains accounted for most clusters (81%, 218/269). In-depth analyses revealed heterogeneity in transmission potential among L4 sublineages, underscoring the importance of sublineage-level resolution. Strains of sublineages L4.1.2.1, L4.8, and L4.3 were detected in patients born in over 15 regions each, with >57% of cases from Europe, supporting their representation as globally successful generalist lineages.
conclusionsMigration substantially increased the genetic diversity of the Mtbc population in Hamburg but did not fundamentally alter local transmission dynamics. Transmission remained lineage-specific and was predominantly driven by established L4 strains, suggesting that successful transmission is mediated by locally adapted sublineages. Predominant L4.1.2.1 and L4.8 sublineages occurred in individuals from a wide range of countries, supporting the generalist-specialist hypothesis at the sublineage level. These findings highlight the interplay between pathogen characteristics and host demographics in shaping transmission and the value of integrating genomic, demographic, and epidemiological data to distinguish imported cases from sustained local transmission in low-incidence settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.